02/06

2021

Qingfeng won the bid for the fourth batch of national volume based procurement for two products
On February 3, Shanghai Yangguang Pharmaceutical Purchasing Network officially released the bidding results of fourth batch of national volume based procurement. Jiangxi Shanxiang Pharmaceutical Co...

11/16

2020

Xinkang® Lacosamide injection was approved by NMPA
On November 4, Xinkang® Lacosamide injection, declared by Jiangxi Qingfeng Pharmaceutical Co., Ltd., was approved by NMPA and deemed to have passed the consistency evaluation. This is the first ...

09/17

2020

Shanghai Denovo officially launches Phase I clinical study of a new TLR8 agonist DN1508052-01
On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at Shangh...
NEWS
R&D

Innovation Platform

R&D Talents

R&D Results

Research Cooperation
Qingfeng Pharmaceutical Group Co.Ltd
Location：8 Zhandong Av., Zhanggong, Ganzhou, Jiangxi Province, China
Phone：+86-0797-5560800,5560600 Fax: +86-0797-5560620